Skip to main content
PSNL
NASDAQ Industrial Applications And Services

Personalis Secures Expanded Medicare Coverage for NeXT Personal Test in Breast Cancer Monitoring

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$7.98
Mkt Cap
$832.533M
52W Low
$3.84
52W High
$11.5
52W Position info
108% above low
Off High info
31% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

PSNL has more than doubled off its 52-week low of $3.84.

Summary

Personalis announced expanded Medicare coverage for its NeXT Personal test, now including monitoring treatment response for specific breast cancer types, which is crucial for its commercial strategy and revenue potential.


Key Events · Product Development and Regulatory · PSNL

  • Expanded Medicare Coverage

    The Centers for Medicare & Medicaid Services (CMS) expanded Medicare coverage for Personalis's ultrasensitive NeXT Personal test. This new coverage includes monitoring treatment response to neoadjuvant therapy in patients with Stage II-III Triple-Negative Breast Cancer or HER2-positive breast cancer.

  • Boosts Market Access

    This expansion significantly broadens the addressable market for the NeXT Personal test, enhancing its commercial viability and potential for revenue growth in a critical oncology segment.


Analysis · PSNL · Industrial Applications And Services

This expanded Medicare coverage for the NeXT Personal test to include monitoring treatment response in Stage II-III Triple-Negative and HER2-positive breast cancer patients is a significant positive development. It broadens the market for Personalis's key diagnostic product, directly impacting potential revenue growth and commercial adoption. This news is particularly important given the company's recent financial challenges and its focus on clinical growth, following previous Medicare coverage expansions.

How filings like this one have moved

In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PSNL was trading at $7.98 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $832.5M. The 52-week trading range was $3.84 to $11.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PSNL - Latest Insights

PSNL
Aug 31, 2026, 5:20 PM EDT
Filing Type: SC 13E3
Importance Score:
8
Price at Filing: $16.70
Real-time Price: $16.33 info
Change: -$0.370 (-2%) info
Market Cap: $1.744B info
PSNL
Aug 04, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $13.29
Real-time Price: $16.33 info
Change: +$3.04 (+23%) info
Market Cap: $1.744B info
PSNL
Jul 20, 2026, 5:26 PM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $13.30
Real-time Price: $16.33 info
Change: +$3.03 (+23%) info
Market Cap: $1.744B info
PSNL
Jul 20, 2026, 9:19 AM EDT
Filing Type: 425
Importance Score:
10
Price at Filing: $14.43
Real-time Price: $16.33 info
Change: +$1.90 (+13%) info
Market Cap: $1.744B info
PSNL
Jul 20, 2026, 9:18 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $14.43
Real-time Price: $16.33 info
Change: +$1.90 (+13%) info
Market Cap: $1.744B info